An interventional study of Sodium Hyaluronate in Facial Dryness and Facial Dullness, sponsored by IBSA Farmaceutici Italia Srl. Recruiting at 6 sites in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-06.
Sponsored by IBSA Farmaceutici Italia Srl (part of IBSA Institut Biochimique SA) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of the study is to evaluate the safety and efficacy of sodium hyaluronate 32 mg/ml in improving facial skin dryness and dullness. Subjects are randomized to the treatment group or to the control group. Only subjects in the treatment group are treated by intradermal injection.
This is a prospective multi-center clinical investigation. Enrolled subjects are randomized to the treatment group or to the no-treatment control group. The treatment group will receive intradermal injections of sodium hyaluronate 32 mg/ml. The improvement of facial skin dryness and dullness will be evaluated at multiple timepoints.
IBSA Farmaceutici Italia Srl is the lead sponsor of 12 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The treatment group will receive intradermal injections of sodium hyaluronate
Device: Sodium Hyaluronate
The control group will not receive any treatment
Sodium Hyaluronate 32 mg/ml
GAIS (Global Aesthetic Improvement Scale) - Blinded evaluator
Treatment effective rate (third-party blinded investigator assessment)
Time frame: 12 week
GAIS-Blinded evaluator
Treatment effective rate (third-party blinded investigator assessment)
Time frame: 4week, 8week, 10week, 16week, 20week
GAIS-Investigator
Treatment effective rate (treating investigator assessment)
Time frame: 4week, 8week, 10week, 12week, 16week, 20week
GAIS-Subject
Treatment effective rate (subject assessment)
Time frame: 4week, 8week, 10week, 12week, 16week, 20week
Improvement of skin moisture
Corneometer assessment
Time frame: 4week, 8week, 10week, 12week, 16week, 20week
Skin dryness improvement assessment - Investigator
Dryness improvement assessment will be performed by the treating investigator. The following scoring will be applied: -1: worse, 0= no change, 1=improvement.
Time frame: 4week, 8week, 10week, 12week, 16week, 20week
Skin dryness improvement assessment - Subject
Dryness improvement assessment will be performed by the subect. The following scoring will be applied: -1: worse, 0= no change, 1=improvement.
Time frame: 4week, 8week, 10week, 12week, 16week, 20week
Skin dullness improvement assessment - Investigator
Skin dullness improvement assessment will be performed by the treating investigator. The following scoring will be applied: -1: worse, 0= no change, 1=improvement.
Time frame: 4week, 8week, 10week, 12week, 16week, 20week
Skin dulless improvement - Subject
Skin dullness improvement assessment will be performed by the subject. The following scoring will be applied: -1: worse, 0= no change, 1=improvement.
Time frame: 4week, 8week, 10week, 12week, 16week, 20week
Subject treatment satisfaction assessment scale
For the question "How do you feel satisfied with the treatment effect of the investigational product?", the answer criteria are from 1 to 5, where 1= very dissatisfied and 5= very much satisfied.
Time frame: 4week, 8week, 10week, 12week, 16week, 20week
Red blood cell (RBC)
Time frame: 0week, 12week, 32 week
White blood cell (WBC)
Time frame: 0week, 12week, 32 week
Platelet count (PLT)
Time frame: 0week, 12week, 32 week
Hemoglobin (HGB)
Time frame: 0week, 12week, 32 week
Serum alanine aminotransferase (ALT)
Time frame: 0week, 12week, 32 week
Serum aspartate aminotransferase (AST)
Time frame: 0week, 12week, 32 week
Serum urea nitrogen/urea (BUN/Urea)
Time frame: 0week, 12week, 32 week
Serum creatinin (Cr)
Time frame: 0week, 12week, 32 week
Blood glucose (GLU)
Time frame: 0week, 12week, 32 week
Urine pH
Time frame: 0week, 12week, 32 week
Urine glucose
Time frame: 0week, 12week, 32 week
Urine protein
Time frame: 0week, 12week, 32 week
Urine specific gravity
Time frame: 0week, 12week, 32 week
Urine red blood cell count
Time frame: 0week, 12week, 32 week
Urine white blood cell count
Time frame: 0week, 12week, 32 week
Urine nitrite
Time frame: 0week, 12week, 32 week
Prothrombin time (PT)
Time frame: 0week
Activated partial thromboplastin time (APTT)
Time frame: 0week
Thrombin time (TT)
Time frame: 0week
Fibrinogen (FIB)
Time frame: 0week
Blood pressure (mmHg)
Systolic blood pressure and diastolic blood pressure will be measured
Time frame: 0week, 4week, 8week, 10week, 12week, 16week, 20week, 32week
Temperature (°C)
Time frame: 0week, 4week, 8week, 10week, 12week, 16week, 20week, 32week
Respiration rate
Times/min
Time frame: 0week, 4week, 8week, 10week, 12week, 16week, 20week, 32week
Heart rate
Beats/min
Time frame: 0week, 4week, 8week, 10week, 12week, 16week, 20week, 32week
Incidence rate of adverse events (AEs)
Incidence rate (%) and number of adverse events (AEs)
Time frame: 0week, 1week, 2week, 4week, 5week, 6week, 8week, 9week, 10week, 12week, 16week, 20week, 32week
Incidence rate of serious adverse events (SAEs)
Incidence rate (%) and number of serious adverse events (SAEs)
Time frame: 0week, 1week, 2week, 4week, 5week, 6week, 8week, 9week, 10week, 12week, 16week, 20week, 32week
Incidence rate of adverse device effects (ADE)
Incidence rate (%) and number of adverse device effects (ADE)
Time frame: 0week, 1week, 2week, 4week, 5week, 6week, 8week, 9week, 10week, 12week, 16week, 20week, 32week
Incidence rate of serious adverse device effects (SADE)
Incidence rate (%) and number of serious adverse device effects (SADE)
Time frame: 0week, 1week, 2week, 4week, 5week, 6week, 8week, 9week, 10week, 12week, 16week, 20week, 32week
Incidence rate of injection site reactions
Incidence rate (%) and number of injection site reactions
Time frame: 1week, 2week, 4week, 5week, 6week, 8week, 9week, 10week
Incidence rate of device deficiencies
Incidence rate (%) and number of of device deficiencies
Time frame: 0week, 4week, 8week
Started Feb 2025 (actual). Primary completion is estimated for Nov 2025, 9 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IBSA Farmaceutici Italia Srl →